NCT06556147View on ClinicalTrials.gov

A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

February 14, 2025

Study Completion Date

May 31, 2027

Conditions
Healthy Volunteers
Interventions
BIOLOGICAL

VXB-241 60 mcg (Low Dose)

VXB-241 low dose, single, IM injection.

BIOLOGICAL

VXB-241 120 mcg (Medium Dose)

VXB-241 medium dose, single, IM injection.

BIOLOGICAL

VXB-241 240 mcg (Medium-high Dose)

VXB-241 medium-high dose, single, IM injection.

BIOLOGICAL

VXB-241 480 mcg (High Dose)

VXB-241 high dose, single, IM injection.

BIOLOGICAL

VXB-241 240 mcg

VXB-241 240 mcg (RSV preF 120 mcg + hMPV preF 120 mcg) (based on 1 month post 1st IMP injection results) single, IM injection.

OTHER

Placebo

Placebo, single, IM injection.

BIOLOGICAL

Arexvy 120 mcg

Arexvy 120 mcg, single, IM injection.

Trial Locations (4)

3153

Veritus Research, Bayswater

4101

University of the Sunshine Coast, South Brisbane

4506

University of the Sunshine Coast, Morayfield

4556

University of the Sunshine Coast, Sippy Downs

All Listed Sponsors
lead

Vicebio Australia Proprietary Limited

INDUSTRY

NCT06556147 - A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults | Biotech Hunter | Biotech Hunter